NEW USSR LIVER PREPARATION ANTIANEMIN

• Document Type: CREST
• Collection: General CIA Records
• Document Number (FOIA) /ESDN (CREST): CIA-RDP80-00809A000700230136-4
• Release Decision: RIPPUB
• Original Classification: C
• Document Page Count: 3
• Document Creation Date: December 22, 2016
• Document Release Date: July 13, 2011
• Sequence Number: 136
• Publication Date: May 13, 1955
• Content Type: REPORT

Sanitized Copy Approved for Release 2011/07/14: CIA-RDP80-00809A000700230136-4
CLASSIFICATION
CENTRAL INTELLIGENCE AGENCY REPORT
INFORMATION FROM
FOREIGN DOCUMENTS OR RADIO BROADCASTS CD NO.
COUNTRY ussR
DATE OF
SUBJECT Scientific - Medici INFORMATION
me
, emopoiesis, radiation
sickness
DATE DIST. /3 May 1955
NO. OF PAGES 3
SUPPLEMENT TO
REPORT NO.
THIS IS UNEVALUATED INFORMATION
PUBLISHED Irregular periodical
WHERE
PUBLISHED 1:oscow
DATE
PUBLISHED 1953
LANGUAGE Russian
..,? .......
T .
., ........ .... ... ....~~........
--- --------- -
Sovremennyye Probleu~y Gematologii i Perelivaniya Krovi, No 3n,
Yt ~: G (4
113,1 USSR LIVER PREPARATION ANrIANFbIIN
Kh. Kh. Vlados (deceased), E. I. Terent'yeva,
M. G. Kakhatelidze, T. A. Cherntsova
[Comment: In addition to the applications mentioned below,
the new Soviet liver preparation antianemin has been recommended
for use in the treatment of disturbances of the blood formation
mechanism that arise in connection with radiation sickness (cf.
+. V. Kozlova, "Radiation Sickness," Vestnik Rentgenolo ii i
RudioloGii, No 4, 1954, pp 38-43). In -view of the emphasis placed
on the activity of cobalt in the discussion below, one may con-
clude that various drugs containing cobalt, in combination with
liver preparations or without them, will presumably be investi-
gated in the USSR, or are being investigated there at present
with the view of using them for the treatment of disturbances of
hemopoiesis. The following report is based on a contribution
from the Central Institute of Hematolo, and Blood Transfusion.]
The liver preparation antianemin, which is being proposed by us for the
treatment of anemia, has been prepared by the Central Scientific Research
Laboratory of Organotherapeutic Preparations ["Organopreparaty"] attached
to the Meat Combine[not further identified] and tested by us from the stand-
point of its hemopoietic activity. To establish whether or not preparations
of this type are therapeutically effective, it is necessary to demonstrate
that they have hemopoietic activity. Hitherto no method has been available
which made possible a reliable qualitative and quantitative determination of
the activity of liver preparations. Singers test, a reticulocytic reaction
used for the determination of hemopoietic substances in gastric juice, does
not yield any quantitative data. Furthermore, the Singer test is not precise,
because reticulocytosis cannot serve as a reliable indication by reason of
its instability in the experimental animals used (rats).
STATE
ARMY
CLASSIFICATION
Sanitized Copy Approved for Release 2011/07/14: CIA-RDP80-00809A000700230136-4
 Sanitized Copy Approved for Release 2011/07/14: CIA-RDP80-00809A000700230136-4
The Cytological Laboratory [of the Central Scientific Research
Institute of Hematology and Blood Transfusion] has developed a method of
hemocultures which enables us to establish qualitative and quantitative
differences in the activity of hemopoietic substances contained in various
liver preparations. With the aid of this method of tissue culture, more
than 200 liver preparations obtained by procedures which differed in various
details were tested under laboratory conditions.
The results of the laboratory investigations showed that the prepara-
tion which has been named by us antianemin is more active than campolon or
the standard grade c: liver extract.
The advantages of antianemin in comparison with the available liver prepa-
rations are the simplicity of the method of preparation and its relatively low cost.
The liver preparation antianemin, into the composition of which we intro-
duced cobalt, has baen prepared by the Central Scientific Research Laboratory
of Organotherapeutic Preparations in forms suitable for intramuscular adminis-
tration and for peroral use. After antianemin had been tested for effective-
ness and subjected to various biological tests, such as checks for sterility,
tests for absence of toxicity, and determination of the effect on blood pres-
sure, it was referred to the Hematological Clinic of the Institute [Central
Institute of Hematology and Blood Transfusion].
Investigations dealing with the effect of cobalt on hemopoiesis were
originally published in 1929. After being administered in small doses, co-
balt exerts a stimulating effect on the bone marrow and for that reason con-
tributes to producing a rise in the level of hemoglobin, erythrocytes, and
reticulocytes in the peripheral blood. In experiments carried out on rate,
it was established that cobalt produces polyglobulism. When cobalt is intro-
duced into the organism, no reduction of the oxidative capacity of the blood
takes place and no effect on the formation of methemoglobin in the blood is
observed. Cobalt is easily eliminated from the body. According to the data
of Berzin and Koval'skiy, a dose of cobalt amounting to one gram per 100 kilo-
grams of weight of the body of a calf does not produce any deleterious effect.
Cobalt is widely used in the therapy of some nervous and infectious diseases
and also in the treatment of anemias of various origin.
Analysis of the ash of crystalline vitamin B12 that has been isolated from
liver indicates that this ash, in addition to phosphorus, contains a large
amount of cobalt, i.e., close to 4 percent. Vitamin B12, in addition to exert-
ing an active effect on erythropoiesis in pernicious anemia and other forms of
anemia, is also a growth factor.
At the hematological clinic, antianemin containing cobalt was administered
to 38 patients. Twenty-seven of these patients received the drug parenterally.
Nineteen of the patients treated had the Addison-Biermer disease, while eight
had other forms of anemia (sprue, chloranemia, anemia following resection of the
stomach, hemolytic anemia, and macrocytic anemia).
In treating the 19 patients who had the Addison-Biermer disease, 2-4 grams
of antianemin were administered per day. The total quantity administered during
the course of treatment amounted to 44-1C0 grams. An increase in the quantity
of hemoglobin amounting from 21-44 percent to 61-77 percent and comprising one
percent per day was observed, while the number of erythrocytes increased from
930,000 to 3,500,ooo-4i370,000. There was also an increase in the number of
leukocytes and thrombocytea. Immature forms of granulocytes disappeared, and
the number of lymphocytes approached normal. No recurrence of the disease was
observed in 16 patients, while three patients had recurrences within 7, 12, and
14 months, respectively., after completion of the course of treatment.
Sanitized Copy Approved for Release 2011/07/14: CIA-RDP80-00809A000700230136-4
 Sanitized Copy Approved for Release 2011/07/14: CIA-RDP80-00809A000700230136-4
C-O-ITT-F-I-D-E-N-T-I-A-y
During treatment with antianemin, toxic phenomena or infiltrations at
the sites of ,injectipn were not observed. When E00-1,875 grams of antianemin
were administered perorally during 13-47 days for the treatment of the forms of
anemia mentioned above, an increase in the quantity of hemoglobin and in the
number of erythrocytes was observed.
The average daily increase by one percent of the quantity of hemoglobin,
which has been achieved by administering antianemin containing cobalt, is
higher than that attained with the use of other liver preparations. Antianemin
must be assumed to be a more effective preparation than campolon, because its
application results in an earlier abatement of the symptoms of anemia.
C-O-N-F-I-D-E-N-T-I-A-L
Sanitized Copy Approved for Release 2011/07/14: CIA-RDP80-00809A000700230136-4